Search This Blog

Saturday, December 3, 2022

'Fed Could Be Pushed by Overheated Wages to Higher Peak Rates'

 Federal Reserve officials have enough worrisome inflation data to consider raising interest rates to a higher peak than investors expect and potentially follow the half-point hike they’ve signaled this month with the same again in February.

Monthly wages rose at the strongest pace since January and US employment surged more than forecast last month, a report showed Friday. That will concern Fed Chairman Jerome Powell, who this week cautioned that slacker job-market conditions and less-lofty earnings growth were needed to cool an inflation rate near a 40-year high.

Powell and his colleagues, now in their pre-meeting blackout, have strongly suggested they would downshift to a half-point move at their Dec. 13-14 gathering, after four straight 75 basis-point increases. He’s also said they likely will need higher rates than they thought in September, when the median forecast saw them at 4.6% next year from a current target range of 3.75% to 4%.

“Powell has suggested that we’re not in a wage-growth spiral yet, but that risk is still there,” said Rhea Thomas, senior economist at Wilmington Trust Co. “This keeps in play this idea that they may have to raise the peak rate and potentially keep it in place for longer.”

Bets on a downshift to a half-point hike this month were intact after the employment report and investors saw the likelihood of the same again at the Fed’s Jan. 31-Feb. 1 meeting as roughly balanced. Pricing in futures markets shows rates peaking around 4.9% next year.

Officials will update their quarterly forecasts at the December meeting and could lift their median projection for the rate peak next year to 5% or above. St. Louis Fed President James Bullard has called for a minimum 5.25% peak and some analysts, including Diane Swonk, chief economist at KPMG LLP, see rates as high as 5.5%, with the Fed willing to cause a recession if necessary to restore price stability.

“Inflation is like a cancer: if not treated, it metastasizes and becomes much more chronic,” Swonk said. “The cure” of higher rates means “it’s going to be a rough 2023.”

Fed officials will get an additional consumer-price report before the December meeting and have another month of data to mull before they gather again early next year.

Powell on Wednesday said rising wages are likely to be “a very important part of the story” on inflation. While supply-chain difficulties seem to be easing for goods, helping the price outlook in that sector, he said wages are the largest cost for the services sector, so labor conditions are key to understanding the outlook on prices on everything from hotels to haircuts.

The jobs report showed average hourly earnings jumped 0.6% in November in a broad-based gain that was the biggest since January, and were up 5.1% from a year earlier. Wages for production and nonsupervisory workers climbed 0.7% from the prior month, the most in almost a year. The pace of pay raises is inconsistent with the Fed’s 2% inflation target.

“Pressures remain in the labor market and if anything are as bad as they’ve been,” said Vincent Reinhart, chief economist at Dreyfus and Mellon. “They want a little more real restraint given that they believe -- at least Powell believes -- inflation pressures are embedded deeply into the consumer price basket.”

While central bankers have set a goal of below-trend growth to cool price pressures, the addition of 263,000 jobs last month -- leaving the unemployment rate at 3.7% -- is the latest evidence that the US economy remains resilient. Growth in the fourth quarter may be 2.8%, well above estimates of what is sustainable in the loing term, according to the Atlanta Fed’s tracking estimate.

While Fed leaders have suggested there’s scope to moderate to 50 basis points this month, they have sought to shift the focus of investors to where rates peak from the size of moves made at each meeting.

They have also emphasized the cumulative impact of prior increases and the notion that policy works with a lag. That’s encouraged speculation they could step down to 25 basis-point moves next year to reduce the risk they go too far.

Even so, the latest jobs report could prod officials to consider another 50 basis points early next year.

“The Fed -- and Powell in particular -- is very much focused on labor-market driven sources of inflation and this report will keep him on high alert,” said Thomas Costerg, senior US economist at Pictet Wealth Management. “I think they can carry on with another 50 at the following Fed meeting.”

The labor force is growing much more slowly than expected, with 3.5 million fewer workers than expected after Covid-19 prompted early retirements and changed work patterns starting in 2020. That’s not seen changing anytime soon.

“This labor shortage has helped feed inflation,” Richmond Fed President Thomas Barkin said Friday, and with US baby boomers retiring, that’s likely to continue over the long term. Even though the Fed has quickly raised rates, “we have seen labor demand continue to run ahead of supply,” he said.

At the upcoming meeting, Fed officials may also want to highlight their steadfastness on higher rates to lean against Wall Street, which has reacted to the planned downshift with an easing of financial conditions that may be unwelcome. The Fed has been deliberately trying to tighten conditions to reduce demand and ease price pressures.

“Broader financial conditions are getting easier. It’s not clear to me that the Fed’s making a lot of progress.” said Stephen Stanley​, chief economist, for Amherst Pierpont Securities LLC. “The Fed has a lot of work to do still to cool the economy off enough and in particular the labor market enough to get to where they want to be on inflation. We’re certainly not there yet.”

https://finance.yahoo.com/news/fed-could-pushed-overheated-wages-130000304.html

Apple looking to move iPhone production out of China in wake of violent worker protests

 Apple Inc., is accelerating its plan to move iPhone production out of China in the wake of violent worker protests over COVID regulations at the world’s largest iPhone factory, a report by the Wall Street Journal said Saturday. 

The plant, dubbed iPhone City, made headlines in recent weeks after workers revolted over COVID-related concerns with security officers decked out in hazmat suits.

Apple is reportedly looking to shift its production toward other nations in Asia like India and Vietnam and to reduce dependence on Taiwanese electronics manufactures like Foxconn which owned the facility in Zhengzhou.

Apple China

In this photo provided Nov 23, 2022, security personnel in protective clothing attack a man during protest at the factory compound operated by Foxconn Technology Group who runs the world's biggest Apple iPhone factory in Zhengzhou in central China's (AP Photo / AP Newsroom)

But according to a report by CNN earlier in the week, Foxconn may also be looking to shift its work outside mainland China.

TickerSecurityLastChangeChange %
AAPLAPPLE INC.147.81-0.50-0.34%

It is unclear exactly when Apple will be able to fully shift its dependence on the iPhone City facility that houses some 300,000 workers and at one point accounted for 85 percent of the Pro lineup of iPhones, according to the report. 

But the decision by Apple comes after years of manufacturing woes stemming from the coronavirus pandemic, supply chain issues and strained geopolitical relations between Washington and Beijing which have lent to a more complicated business plan. 

In this photo provided Nov 23, 2022 employees at the world's biggest Apple iPhone factory were beaten and detained in protests over pay amid anti-virus controls, according to witnesses and videos on social media Wednesday, as tensions mount over Chin (Associated Press / AP Images)

placeholder

"In the past, people didn’t pay attention to concentration risks," Alan Yeung, a former U.S. executive for Foxconn, told the Wall Street Journal. "Free trade was the norm and things were very predictable. Now we’ve entered a new world."

Apple may also look to rely on a larger pool of assemblers even from within China in order to circumvent supply-chain snafus, while the company also looks to secure reliable manufactures that can handle what Apple calls new product introduction, or NPI.

According to the report, NPI is the process in which Apple translates the blueprints of its latest product into a detailed manufacturing plan – a step nations like India and Vietnam may not yet be able to accommodate. 

"Finding all the pieces to build at the scale Apple needs is not easy," Kate Whitehead, a former Apple operations manager told the publication. 

Fox News Digital could not immediately reach Apple for comment. 

https://www.foxbusiness.com/markets/apple-looking-move-iphone-production-china-wake-violent-worker-protests-report

Hollywood’s Latest Diet Craze? Ozempic, Insulin Drug With Vanishing—Literally—Side Effects

 Under a rehearsal piano in a studio on the MGM lot in Hollywood in 1952, Debbie Reynolds crumbled. She was in the middle of preparing for Singing in the Rain, which would be her first leading role for the studio, alongside Gene Kelly, and the first time she’d have to dance, really. She was 19 years old, had three teachers, and was spinning around eight hours a day. It hurt everywhere, she wrote in her autobiography 60 years later, “most of all my brain and my feet.” She lay there, under that piano, until Fred Astaire materialized to coax her back up. She wasn’t going to die, he told her. If you’re not sweating, you’re not doing it right. So she shot “Good Morning” from eight in the morning till eleven o’clock that night. When it was over, she collapsed. For days, she didn’t get out of bed at her doctor’s behest. The studio had its own MD, who wanted to administer what they called a “vitamin shot”—amphetamines. Possibly, the same ones, Reynolds wrote, that “ruined Judy Garland.”

Since its inception, Hollywood has been the land where unrealistic beauty standards collide with financial pressure that hinges on its stars keeping thin, energetic, and always ready to make more hits. And there’s always been a quick fix or two. Since Reynolds’s era, the nature of the fixes have evolved from “vitamin shots” and “pep pills” to phen-fen to Adderall to clenbuterol—a medication used to treat breathing problems in horses. That’s to say nothing of the extra-medicinal aesthetic boosts by way of CoolSculpting, injectables, and Brazilian butt lifts, which suck pockets of fat from one part of a body and insert them into another, in order to create a generation of Instagram-age Jessica Rabbits.

It should have been no mystery, then, that when the people of Hollywood started dropping dozens of pounds in a matter of weeks, it wasn’t that everyone had suddenly started practicing moderation and logging 10,000 steps. It seemed like overnight everyone knew someone who was injecting semaglutide, whose brand name is Ozempic. The insulin regulator, developed by the Danish pharmaceutical giant Novo Nordisk in 2012, won FDA approval to treat type 2 diabetes five years later. It works by stimulating insulin release, which helps lower blood sugar levels and slow down food leaving the stomach, in turn making Ozempic users feel satiated for longer periods of time. When doctors noticed that patients using Ozempic were losing weight as a side effect of the drug, Novo Nordisk saw opportunity, conducting clinical trials on obese and overweight individuals to find that its drug did, in fact, lead to weight loss of about 15 percent of body mass in a few weeks or months. Soon the manufacturer started marketing a higher-dose semaglutide, called Wegovy, to treat obesity. Injections, which, mostly, people give themselves once per week, usually take six to eight weeks to cause significant weight loss.

“Ozempic is a real lifeline for people, and for those who need it, what it’s teaching people to do is exactly what we should be doing: eating often and eating smaller amounts of food in order to balance your blood sugars, because the longer we can have balanced blood sugars, the longer our lives will be, and the more balanced our blood sugar, the less diseases we will have in life,” said Kim Shapira, a registered dietitian and celebrity nutrition therapist who’s been in practice in Los Angeles for 25 years and sees 50 private clients each week. “The average American gained 29 pounds in COVID, and so losing that weight will decrease your risk of high cholesterol, cardiovascular disease, having a stroke, diabetes, high blood pressure, and high triglycerides. And it’s taking away emotional eating, because they’re now physically in tune with what their body can and cannot eat.” The problem, she said, is not Ozempic. It’s people looking for a quick fix, or people who don’t really need the drug, or the absence of other professional help to address the roots of their issues.

Which, anecdotally in Hollywood anyway, seems to be the people who are seeking out Ozempic. When a preposterously famous star very publicly shed a great deal of weight in a short window of time, people wanted what she was having. The onscreen talent dropping weight led to off-screen producers and bosses and friends trying it too. Then came the socialite brides prepping for their nuptials, new moms eager to lose baby weight, Brentwood ladies whispering at school drop, full-bellied businessmen who’d ditched their Pelotons, and the various Instagram famous discussing it on their way to work out at Dogpound. Some people who are concerned enough about vaccine safety to delay their children’s immunization schedules but who have made peace with Botox have also found comfort with Ozempic. As one observer explained to me, finding out that all of these people weren’t just magically losing significant amounts of weight was sort of like when Dorothy’s world all of a sudden goes Technicolor. Some claim there is a off-label tell—a gaunt face, the if-you-know-you-know signature. “Once you know it exists, you start to see Ozempic everywhere.”

Those whose eyes are open to it are getting the drug through a crosstab of specialists—high-profile endocrinologists, ob-gyns, cardiologists—some of whom people say are looser with their justifications for prescribing it. The real proliferation has happened through telemedicine. Several people I spoke with told me that they’ve heard of people lying about their weight on video chats with doctors in order to get the prescription (the party line is that your body mass index has to indicate that you are obese). The drug’s side effects, which mainly occur as someone starts Ozempic, make it easier to lose weight initially. “I haven’t seen anybody not experience nausea, which can be very upsetting and crippling for like two or three days,” Shapira told me, adding that most of her clients have had to take the anti-nausea pill Zofran to counteract it. Along with the nausea further suppressing their appetite, the Ozempic takers I spoke to have told me that it’s given them headaches, making alcohol less pleasurable. And because blood sugar levels change, some are so bone-crushingly tired that they aren’t going out to dinner as often.

With qualifying insurance, people can pay as little as $25. But some in Hollywood are paying out of pocket, up to $1,500 per month. The demand has overwhelmed pharmacies and made it difficult for people who actually need Ozempic to get their prescription on time. This fall, the Therapeutic Goods Administration in Australia issued a statement asserting that there is a shortage of semaglutide injections “due to an unexpected increase in consumer demand…[which is] significantly affecting people using Ozempic for its approved use for type 2 diabetes.” The TGA expects the shortage to continue for months and urged prescribers to consider alternatives. It’s extended in Los Angeles, where pharmacists are urging people who have a prescription to refill it as early as possible to avoid a potential shortage when they need the medication.

There has been no long-term study of the drug for people without blood sugar diseases taking the medication. And less of a guide for those tired of feeling tired or nauseous or injecting themselves or paying thousands of dollars a year to poke themselves with a drug people don’t know much about other than it seems to work. Because the drug is relatively new, it is unclear what the long-term effects could be, particularly if someone is not diabetic. How long can someone using it off-label stay on it? As Bravo’s Andy Cohen tweeted earlier this fall, “Everyone is suddenly showing up 25 pounds lighter. What happens when they stop taking#Ozempic ????”

Shapira said that those who haven’t been working with a registered dietitian or made real lifestyle changes alongside taking the injections are likely to gain back the weight that they lost. Which would be a throwback, in a sense. “We saw with phen-fen and any of the other weight loss drugs that people didn’t learn anything and that they didn’t change any of their habits.” She added: “I’m worried about the long-term effects of people who only look at things short term.” 

https://www.vanityfair.com/hollywood/2022/11/ozempic-hollywood-diet-drug

NY cannabis launch turning into bad trip: 'social justice' critics

 The launch of New York’s legal cannabis industry is turning into a bad trip — even before the first official marijuana stores have opened for business, social justice critics claim.

A group advocating for the first licensed marijuana storefront sellers with prior weed convictions said Friday they’re being set up for failure.

The Cannabis Social Equity Coalition said the first sellers will be required to buy cannabis products from NY hemp farmers of “questionable quality and safety,” are not being adequately trained for the market and will face a mountain of debt.

Under New York’s “seed to sale” cannabis law, the product sold by licensed dispensaries must come from marijuana plants grown by local farmers.

But the group said the “biomass” type of cannabis grown by farmers is not a suitable flower for smoking.

“This type of cannabis is considered low grade, best suited for processing into oils, vapes, topicals and edible cannabis products. It is not suitable as a smokable flower for sale at dispensaries,” Reginald Fluellen of the Cannabis Social Equity Coalition said.

He also claimed cannabis grown by these Hemp farmers contains a “high amount of bacteria, yeast and mold.”

Chief Equity Officer of the NYS Office of Cannabis Management Damian Fagon smells a cannabis plant as he takes a tour of Claudine Field Apothecary farms on Oct. 7, 2022 in Columbia County, New York.
Office of Cannabis Management’s Damian Fagon argues New York’s first adult-use dispensaries will sell products tested for many potentially harmful elements.
Getty Images

The state Office of Cannabis Management disputed the claim that it has authorized the growth and sale of bad weed.

“Let’s stick to the facts, and they’re clear: New York’s first adult-use dispensaries will be selling products grown by New York family farmers that have been tested for a wide array of potentially harmful elements, including heavy metals, e-coli, aspergillus, and other contaminants in line with practices in other states,” said Damian Fagon, OCM’s chief equity officer.

Meanwhile the Cannabis Social Equity Coalition claimed dispensary owners have not been given the adequate training and incubation support needed to run a highly regulated cannabis business and will be strapped with “high debt and high interest rates on debt repayment, on day one.”

Damian Fagon, Chief Equity Officer at New York State Office of Cannabis Management, speaks to reporters next to marijuana plants for the adult recreational market hanging in a drying room at a farm in Suffolk County, N.Y. on Oct. 4, 2022.
The state Office of Cannabis Management refutes the claim it authorized the sale of bad weed.
AP

OCM disputed these claims as buzz kill.

“These dispensary owners will receive support from the Social Equity Cannabis Investment Fund, breaking down barriers to capital in the complex industry; and they’re able to jumpstart the legal market with delivery sales, growing their capital before they open a storefront,” said OCM’s Fagon said.

He said the first dispensary owners already had a history of running other successful businesses and  “jumping to conclusions about the products they will sell and their ability to be successful will only be damaging to them and our effort to establish the most equitable cannabis market in the nation.”

He also took a shot at the Cannabis Social Equity Coalition as MIA during the public comment process regarding the cannabis regulations.

“We look forward to their input on the regulations for most of the remaining market that were advanced by the Cannabis Control Board last month since we didn’t receive comment from them on the regulations for this dispensary program,” said Fagon.

Cannabis flower in a jar
Under New York’s “seed to sale” law, the product must come from marijuana plants grown by local farmers.
ZUMAPRESS.com

Still, there’s little doubt that the budding cannabis program is facing challenges.

The latest criticism comes a day after revelations surfaced that former NBA star Chris Webber, selected by the state to help raise $200 million in a public-private partnership for the emerging legal weed industry, has failed to raise any cash.

Two days ago, a study revealed that there are “likely tens of thousands of illicit cannabis businesses” currently operating out of bodegas, smoke shops and other storefronts in New York City — with many of the pop-up shops selling bad or dangerously tainted weed.

Many of these black market weed sellers are paying little or no tax while the 36 state retail operators awarded licenses by the state last month will have to pay a steep cannabis tax.

That will make it difficult for the legal operators to compete on price with illicit sellers that have sprouted all over the city — including tidy, middle class neighborhoods such as Kew Gardens.

https://nypost.com/2022/12/02/ny-cannabis-launch-turning-into-bad-trip-social-justice-critics/

Scientist who worked at Wuhan lab says COVID was man-made virus

 A scientist who worked at a controversial research lab in China has claimed that COVID was a man-made virus that leaked from the facility, according to a report.

Andrew Huff said COVID leaked from the Wuhan Institute of Virology in China two years ago and blamed authorities for the “biggest US intelligence failure since 9/11,” Britain’s The Sun reported Saturday.

The lab has been at the center of fierce debates about the origins of COVID, with both Chinese government officials and lab personnel denying that the virus leaked from the facility.

A picture of scientist Andrew Huff.
Scientist Andrew Huff said COVID leaked from the Wuhan Institute of Virology in China two years ago.
AndrewHuff.com

Huff, an epidemiologist said in his new book, The Truth About Wuhan, that the pandemic was the result of the US government’s funding of coronaviruses in China.

He said that China’s gain-of-function experiments, which were carried out with lax security, led to a lab leak at the Wuhan lab.

“Foreign laboratories did not have the adequate control measures in place for ensuring proper biosafety, biosecurity, and risk management, ultimately resulting in the lab leak at the Wuhan Institute of Virology,” he said in his book, which was exclusively excerpted in the newspaper.NEXT

Virologists work in the P4 lab of the Wuhan Institute of Virology in Wuhan, China.
Virologists work in the P4 lab of the Wuhan Institute of Virology in Wuhan, China.
A picture of the cover of a book written by Dr. Andrew Huff.
"Foreign laboratories did not have the adequate control measures in place for ensuring proper biosafety, biosecurity, and risk management..." Dr. Huff wrote in his book.

Over the last two years, increasing evidence has suggested that the virus was leaked from the lab.

The Wuhan Institute of Virology, a state-run and funded research facility home to China’s riskiest coronavirus research, has been under immense pressure by the ruling Chinese Communist Party to produce scientific breakthroughs to raise China’s global status despite lacking resources, according to a recent investigation published by ProPublica/Vanity Fair.

https://nypost.com/2022/12/03/scientist-who-worked-at-wuhan-lab-says-covid-man-made-virus/

Lingering Effects Seen With Non-COVID Respiratory Illness Too

 People with acute respiratory illness during the pandemic suffered similar levels of poor well-being in the months afterward whether they tested positive for SARS-CoV-2 or not, a registry study showed.

In a cohort of people who all had initial symptoms suggestive of COVID-19, those who had moderate to severe scores at 3 months on the pain, mood, and other quality-of-life measures on the Patient-Reported Outcomes Measurement Information System (PROMIS) scale were actually less likely to have tested positive for the coronavirus as to have had other causes of illness (39.6% vs 53.5%, P<0.001).

"The presence and persistence of poor mental health among nearly 1 in 4 participants (21.9% of the COVID-19-positive group and 27.3% of the COVID-19-negative group) may reflect a more general pandemic exposure, which participants in both groups experienced," Lauren Wisk, PhD, of the University of California, Los Angeles and colleagues reported in a paper published in JAMA Network Open.

The similarly bad self-reported well-being may be "in part because being seriously sick during a pandemic is incredibly stressful and the pandemic limits your availability of resources to manage your illness (access to healthcare, access to friends and family, etc.)," Wisk told MedPage Today.

The SARS-CoV-2 positive group included both those who were recovered and participants who might have had long COVID, the researchers noted. "Therefore, all results should be interpreted to reflect a more general burden of SARS-CoV-2 infection and the COVID-19 pandemic in addition to any specific burdens associated with long COVID."

Wisk also cautioned against interpreting the study data as evidence that long COVID is an overstated diagnosis. Rather, she told MedPage Today: "I think the takeaway is that long COVID exists -- just as other lingering negative effects after other illnesses -- but that some of what we are classifying as long COVID may be due to the viral infection and some may be due to the broader pandemic impacts."

The researchers did consider the possibility of false-negative tests blurring the findings, Wisk told MedPage Today in an email. "We asked participants if they subsequently tested positive, and only two reported that they had." But because not everyone retests, potential misclassification was a limitation of the study, her group acknowledged.

The study findings also emphasized the importance of concurrent control groups in studying COVID-19 sequelae, the researchers wrote.

Study Critique

David Putrino, PT, PhD, director of rehabilitation innovation at Icahn School of Medicine at Mount Sinai in New York City, expressed concern in a phone interview with MedPage Today that the researchers framed their findings in a way that will do harm to patients.

"Tests are frequently negative. By the time you get the test, the antibodies fade or there are those 20% that do not seroconvert," Putrino said, noting that guidance from the CDC and the World Health Organization indicates that testing is imperfect "and a diagnosis does not need to include a positive test."

"This paper should really be a call to understand that a whole bunch of folks now have long COVID, who also have a negative test on their medical record, which is going to make it harder for them to access short- and long-term disability if their condition progresses," he said.

Self-report would "only capture the tip of the iceberg -- what patients can consciously feel," added Colin D. Furness, MISt, PhD, MPH, of the University of Toronto, in an email to MedPage Today. "Much of what is long COVID isn't perceptible. Vascular damage is painless but can lead to strokes several months later. Brain tissue loss can lead to significant loss in cognitive performance on tests without the person being aware of deficits. Diabetes may take quite a while to diagnose, as would infertility."

All that can be concluded, he argued, "is that all kinds of illnesses can have lingering unpleasant effects, particularly if there are comorbidities."

Study Details

The study included 1,000 adults enrolled in the Innovative Support for Patients with SARS-CoV-2 Infections Registry (INSPIRE) from Dec. 11, 2020, to Sept. 10, 2021, who had acute symptoms suggestive of SARS-CoV-2 infection at the time of testing. There were 722 who had any molecular or antigen-based assay test approved or authorized by the FDA that tested positive for SARS-CoV-2, and 278 who tested negative within the 42 days leading up to enrollment.

Of the participants, two-thirds were women; 15.3% were Hispanic, 70% were white, and 13.4% were Black or African American.

Participants completed the 29-item PROMIS survey and the PROMIS Short Form-Cognitive Function 8a at baseline and at 3-months follow-up. The primary outcome was the mean PROMIS score for the study group and controls.

While scores in both groups were similar overall, when comparing 3 month follow-up to mean baseline PROMIS scores, participants in the test-negative group had less of a mean difference (indicating less improvement) than test-positive participants at 3 months for:

  • Physical function (3.1 vs 6.1 points, P<0.001)
  • Fatigue (-3.5 vs -5.3, P=0.01)
  • Social participation (2.8 vs 6.1, P<0.001)
Researchers highlighted that participants who tested positive had greater overall changes in their social participation at 3 months compared to test-negative participants, noting that "these improvements were concentrated among those who were younger and those who received testing in an ambulatory setting."

At baseline, those in the COVID-19 positive group versus negative group, respectively, reported significantly lower mean scores for anxiety, depression, pain interference, and pain intensity. But mean differences in scores in the two groups from baseline to 3 months were not significant for cognitive function, anxiety, depression, fatigue, sleep disturbance, pain interference, and pain intensity.

There were no significant or clinically meaningful differences in the groups if they got their COVID-19 test in the emergency department or hospital; but for those who received their COVID-19 test in an ambulatory setting, improvements were significantly better for PROMIS results from baseline to 3 months for social participation and cognitive function.

The researchers noted that, "future evaluations of post-COVID-19 sequelae should assess key well-being domains, including social participation, in addition to discrete symptoms, to fully capture the patient experience of long-term decrements in health and well-being. Information on social participation may specifically help to identify COVID-19 experiences for which more intense intervention and/or treatment may be required to return patients to their previous activities of daily living" and "these broader pandemic societal impacts therefore call for increased attention to mental health services irrespective of SARS-CoV-2 infection status."

Further, the researchers said, "these findings suggest that many COVID-19-positive individuals are able to achieve well-being scores that approach the U.S. average but do not imply that all patients with COVID-19 achieve well-being after illness."

Limitations

Researchers said this study was limited by the low diversity of the registry population and potential selection bias due to limited access to a verifiable COVID-19 test and internet-enabled devices to administer study components. Furthermore, the higher-risk population with more severe illness might have been less willing to participate. In addition, people with cognitive impairment may have been less likely to enroll in the study.

The study was also limited by lack of information on the acute conditions that caused illness in the test-negative population (for example, bacterial pneumonia, respiratory syncytial virus, or streptococcal pharyngitis).

"Finding an appropriate comparison group for COVID-19-positive participants is difficult," they noted, and "comparison with this COVID-19-negative group may underestimate the decrement in well-being compared with the general population who do not experience illness."

Study data was also limited to COVID-19 variants circulating in September 2021.

Disclosures

The study was funded by the National Center for Immunization and Respiratory Diseases of the Centers for Disease Control and Prevention (CDC). Wisk had nothing to disclose. Study co-authors reported research grants and consulting fees from academic institutions and industry not related to the study.

Putrino had no conflicts of interest to disclose. Furness had nothing to disclose.